This review is a summary of a recent event in Melbourne to discuss evolving best practice related to irARs and cancer immunotherapy patient management.
This review is a summary of the meeting and case studies presented and is the 2nd of a two-part series. Commentary is provided by Professor Mark Shackleton, Director of Oncology at The Alfred and also Professor of Oncology at Monash University.
Please login below to download this issue (PDF)